C., M., T., B., T., T., S., T., H., V. V., S., Z., . . . G., D. S. (2017). Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study.
Chicago Style CitationC., Moreno, et al. Antiviral Activity of TMC435 Monotherapy in Patients Infected With HCV Genotypes 2-6: TMC435-C202, a Phase IIa, Open-label Study. 2017.
MLA CitationC., Moreno, et al. Antiviral Activity of TMC435 Monotherapy in Patients Infected With HCV Genotypes 2-6: TMC435-C202, a Phase IIa, Open-label Study. 2017.
Warning: These citations may not always be 100% accurate.